Journal of Neuroimmunology
Volume 221, Issue 1 , Pages 121-124 , 15 April 2010

Long-term follow up of thymus in patients with myasthenia gravis

  • Masashiro Sugawara

      Affiliations

    • Department of Neurology, Akita University, Graduate School of Medicine, Akita, Japan
    • Corresponding Author InformationCorresponding author. Hondo 1-1-1, Akita 010-8543, Japan. Tel.: +81 18 884 6104; fax: +81 18 836 2611.
    • ,
  • Chizu Wada

      Affiliations

    • Department of Neurology, Akita University, Graduate School of Medicine, Akita, Japan
    • Medical Education Center, Akita University, Graduate School of Medicine, Akita, Japan
    • ,
  • Satoshi Okawa

      Affiliations

    • Department of Neurology, Akita University, Graduate School of Medicine, Akita, Japan
    • ,
  • Michio Kobayashi

      Affiliations

    • Department of Neurology, Akita University, Graduate School of Medicine, Akita, Japan
    • ,
  • Erika Abe

      Affiliations

    • Department of Neurology, Akita University, Graduate School of Medicine, Akita, Japan
    • ,
  • Koji Obara

      Affiliations

    • Department of Neurology, Akita University, Graduate School of Medicine, Akita, Japan
    • ,
  • Sachiko Kamada

      Affiliations

    • Department of Neurology, Akita University, Graduate School of Medicine, Akita, Japan
    • ,
  • Hirohide Ohnishi

      Affiliations

    • Department of Neurology, Akita University, Graduate School of Medicine, Akita, Japan
    • ,
  • Itaru Toyoshima

      Affiliations

    • Department of Neurology, Akita University, Graduate School of Medicine, Akita, Japan
    • Medical Education Center, Akita University, Graduate School of Medicine, Akita, Japan

Received 18 June 2009 ,Revised 10 November 2009 ,Accepted 24 December 2009.

References 

  1. Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis. J. Neurol. 1997;244:542–547
  2. Kirkove C, Berghmans J, Noel H, van de Merckt J. Dramatic response of recurrent invasive thymoma to high doses of corticosteroids. Clin. Oncol. (R. Coll. Radiol.). 1992;64–66
  3. Konishi Y, Yoshiyama Y, Takamori M, Saida T and the Japanese FK506 MG study group. Long-term treatment of generalized myasthenia gravis with FK506 (tacrolimus). J Neurol. Neurosurg. Psychiatry. 2005;76:448–450
  4. Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y. Efficacy of low-dose FK506 in the treatment of myasthenia gravis — A randomized pilot study. Eur. Neurol. 2005;53:146–150
  5. Newsom-Davis J, Cutter G, Wolfe GI, Kaminski HJ, Jaretzki AIII, Minisman G, et al. Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone. Ann. N. Y. Acad. Sci. 2008;1132:344–347
  6. Ponseti JM, Azem J, Fort JM, López-Cano M, Vilallonga R, Buera M, et al. Long-term results of tacrolimus in cyclosporine- and prednisone- dependent myasthenia gravis. Neurology. 2005;64:1641–1643
  7. Sugawara M, Wada C, Toyoshima I. Treatment of myasthenia gravis —efficacy of thymectomy and immunosupressants-. (Japanese, English abstract available). Neurol. Ther. 2008;25:463–469
  8. Tada M, Shimohata T, Tada M, Oyake M, Igarashi S, Onodera O, et al. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. J. Neurol. Sci. 2006;247:17–20

PII: S0165-5728(10)00003-2

doi: 10.1016/j.jneuroim.2009.12.010

Journal of Neuroimmunology
Volume 221, Issue 1 , Pages 121-124 , 15 April 2010

Article Tools

* Image Usage & Resolution